Atom Investors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Atom Investors’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-16,630	Closed	-$159K	–	598
2019 Q1	$159K	Buy	+16,630	New	+$170K	0.01%	488

Other funds holding SGMO

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Atom Investors's SGMO Position: Q2 2019 in Review

Atom Investors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2019, closing a stake of 16,630 shares — an estimated $159K sold.

Atom Investors first reported a position in SGMO in Q1 2019 and held it in 1 quarter. The position peaked at $159K in Q1 2019. 185 funds tracked by Wall St. Rank hold SGMO as of Q2 2019.

Atom Investors reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2019 after selling out during the quarter.
Atom Investors sold 16,630 SANGAMO THERAPEUTICS INC shares in Q2 2019, an estimated $159K.
Atom Investors first reported a position in SANGAMO THERAPEUTICS INC in Q1 2019 and held it in 1 quarter.
Atom Investors's SANGAMO THERAPEUTICS INC position peaked at $159K in Q1 2019.
185 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2019.

Based on Atom Investors's 13F filing for Q2 2019, filed 14 Aug 2019.